NEWS


Silgan to buy Albea’s dispensing business


Closures manufacturer Silgan Holdings of the US has signed a binding offer to acquire Albea’s dispens- ing business for $900m. The Albea business


makes pumps, sprayers and foam dispensing systems for consumer goods in the beauty and personal care markets. It has ten plants in North America, Europe, South America and Asia, and had sales of about $383m in 2018. The deal should close in the first half of 2020, subject to regula- tory approval and closing conditions.


Silgan said that the acquisition would “expand its position in the dispens- ing markets to include highly engineered foam pumps, fine mist pumps, lotion pumps, samplers and fragrance caps, and closures for personal care and beauty products”. It expects to achieve operational cost synergies of $20m per year within 18 months.


Comar


buys iMark Molding


The Albea business makes pumps and dispensers for lotions and other beauty products


“This would significantly enhance the scope and breadth of our market-lead- ing closures franchise by bringing new products and capabilities in the highly engineered dispensing category, such as fine lotion dispensing solutions for skin care,” said Tony Allott, Chairman and CEO. “The Albea dispensing business is a ‘hand-in-glove’ fit with our closures business.” Silgan has also acquired


Cobra Plastics, which makes injection moulded closures for a wide variety of con-


sumer good applications, particularly aerosol over- caps. Cobra has annual sales of about $30m and has two facilities in Macedo- nia, Ohio. Silgan President Adam Greenlee said: “The combination of Cobra’s overcap product line with our aerosol actuators and dispensing systems will allow Silgan to offer a broader range of integrated solutions, including func- tional overcaps, to meet the unique needs of our customers.” � www.silganholdings.com


US packaging group Comar has acquired iMark Molding, which Comar said would support its growth objectives in the medical and pharmaceutical segments, adding further engineering and custom plastic moulding and assembly capabilities. iMark is based at


Woodville, Wisconsin, where it has an ISO13485-certified 12,000 m2


facility with


over 30 injection mould- ing machines and 1,400 m2


of certified ISO Class


7 cleanroom space. Company president


Mark Sturtevant will continue to manage day-to-day operations. Comar, which is mainly owned by funds man- aged by Morgan Stanley Capital Partners, added that it does not plan any plant closures or employ- ee layoffs. � www.comar.com


ECHA consults on siloxane restrictions


The European Chemicals Agency (ECHA) said in December that its proposal to restrict the use of D4, D5 and D6 siloxanes, which are used in production of silicones and silicone rubbers, including LSR, has been supported by SEAC (Committee for Socio-Economic Analysis) and RAC (Committee for Risk Assessment). The proposal is to restrict placing on


the market D4, D5 and D6 siloxanes as substances, contituents of other substances, or in mixtures in a concen-


4


tration equal or greater than 0.1% w/w of each. A 60-day consultation was launched on 18 December 2019. The proposed restriction has been described as “disproportionate” by Dr Pierre Germain, Secretary General of Cefic sector group Silicones Europe (CES), which represents the sector. He said the decision to characterise the substances based on persistence, bioaccumulative and toxic (PBT) under REACH “did not reflect the latest science.”


INJECTION WORLD | January/February 2020


Germain added that the restriction is aimed at products that directly reach consumer or professional end markets in the EU and that these would generally comply with the 0.1% limit. Industrial uses, he said, are covered by derogations that will allow manufactur- ers to produce D4, D5 and D6 silox- anes, formulate uncured polymers, and sell them to processors without restriction. � www.echa.europa.eu � www.silicones.eu


www.injectionworld.com


IMAGE: ALBEA


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54